ar-c239 has been researched along with colforsin in 1 studies
| Studies (ar-c239) | Trials (ar-c239) | Recent Studies (post-2010) (ar-c239) | Studies (colforsin) | Trials (colforsin) | Recent Studies (post-2010) (colforsin) |
|---|---|---|---|---|---|
| 45 | 0 | 5 | 13,460 | 46 | 1,298 |
| Protein | Taxonomy | ar-c239 (IC50) | colforsin (IC50) |
|---|---|---|---|
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 1.729 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.041 | |
| Adenylate cyclase type 1 | Homo sapiens (human) | 0.0955 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bobirnac, I; Gazi, L; Loetscher, E; Parsley, S; Schoeffter, P | 1 |
1 other study(ies) available for ar-c239 and colforsin
| Article | Year |
|---|---|
Functional alpha2C-adrenoceptors in human neuroblastoma SH-SY5Y cells.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Brimonidine Tartrate; Clonidine; Colforsin; Cyclic AMP; Dose-Response Relationship, Drug; Guanfacine; Humans; Idazoxan; Isoquinolines; Neuroblastoma; Oxymetazoline; Piperazines; Prazosin; Quinoxalines; Receptors, Adrenergic, alpha-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Yohimbine | 1999 |